Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

Mendus Q4'23: New milestones

By Antti SiltanenAnalyst
Mendus

Last year was crucial for Mendus but the company managed to achieve important milestones during the year. Mendus CEO Erik Manting comments highlights of the Q4 and targets for this year in an interview with analyst Antti Siltanen.

Content:
00:00 Introduction
00:20 Mendus in a nutshell
02:33 Focused on maintenance therapy and measurable residual disease
06:27 Cellular immunotherapies
11:08 Safety profile and efficacy of vididencel
14:06 Milestones of 2023 and targets for 2024
17:14 Cash position

Stay up to date
Company management interviews

Recent videos

Orion as an Investment | Life Science Night Dec. 9, 2025
13.12.2025, 12.50 Orion
AKTIER MED FRIIS - UGE 50 2025
12.12.2025, 12.00
HCA Morgenbørs 12/12 - Positive futures og fokus på FLSmidth og fedme aktier
12.12.2025, 09.27 Novo Nordisk
A sit-down with CEO Remco Westermann
12.12.2025, 09.09 Verve Group
Aiforia as an Investment | Life Science Night Dec 9, 2025
11.12.2025, 11.00 Aiforia Technologies
View all videos
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.